Final Program in it's entirety - MyGirlsBlood

Recommendations

Info

Posters, Tuesday and Wednesday Index of Poster Presenters cont’d 35P19 Comparison of Several Automated VWF:RCo Assays for Monitoring of Patients Treated with VWF/FVIII Concentrates: Improved Performance with a New Modified Method Stadler M2 , Hillarp A1 , Janisch S2 , Zapfl C2 , Haderer C2 , Schwartz B3 1 2 Malmö University Hospital, Malmö, Sweden, Octapharma PPGmbH, Vienna, Austria, 3Octapharma U.S.A., Inc., Lafayette Hill, PA, U.S.A. 35P20 Improved Performance Characteristics of the von Willebrand Factor Ristocetin Cofactor Activity Assay (VWF:RCo) Using a Novel Automated Assay Protocol Hillarp A1 , Stadler M2 , Haderer C2 , Weinberger J2 , Kessler C3 , Roemisch J2 1 2 Malmö University Hospital, Malmö, Sweden, Octapharma PPGbmH, Vienna, Austria, 3Georgetown University Hospital, Washington, DC, U.S.A. 35P21 Does the von Willebrand Factor (VWF) Triplet Structure Affect VWF Function? Fuchs B, Solecka B, Kroening M, Kannicht C Octapharma R&D, Molecular Biochemistry Berlin, Berlin, Germany 35P22 Efficiency of Prophylaxis in Patient with Type 3 von Willebrand Syndrome and Recurrent Gastrointestinal Bleeding Krause M1 , Eckardt V2 , Pillitteri D1 , Scholz T1 , Kirchmaier C1 1 2 Haemostaseology and Gastroenterology, Department of Internal Medicine, Deutsche Klinik für Diagnostik, Hessen, Germany 35P23 Use of FVW/FVIII Concentrates for Hysterectomy in VWD Patient Lavalle E1 , Ucar L1 , Citrín E2 Sanatorio Americano, Montevideo, Uruguay 35P24 Treatment of von Willebrand disease by “Immunate” Likhacheva E, Kopylov K, Plyushch O, Severova T Hematological Research Centre RAMS, Moscow, Russia 35P25 Enhanced VWF-GPIb Binding is Associated with a Reduced Thrombogenic Response in Mice with Type 2B von Willebrand Disease Golder M, Pruss C, Hegadorn C, Mewburn J, Sponagle K, Lillicrap D Dept. Pathology & Molecular Medicine, Queen’s University, Kingston, ON, Canada 90 35P26 Correlation between Clinical Data, Laboratory Results and Adverse Reactions after Administration of Desmopressin (DDAVP) Miesbach W 1 , Dueck O 1 , Krekeler S 1 , Schuettrumpf J 1 , Alesci S 1 , Großmann R 2 1 University Hospital Frankfurt, Germany, 2 Gemeinschaftspraxis Laborärzte Schweinfurt, Germany 35P27 Retrospective Analysis of the Clinical Efficacy and Safety of Humate® P in Patients Treated with Humate® P for More Than 5 Years Miesbach W, Asmelash G, Müller S, Haferland I, Krekeler S, Alesci S University Hospital Frankfurt, Germany 35P28 The Psychosocial Issues Which Impact Children in NM who have von Willebrand Disease Halona M, Montoya R, Mathew P Ted R.Montoya Hemophilia Program, Albuquerque, NM, U.S.A. 35P29 Clinical Situation in Patients with von Willebrand Disease in Combination with a Newly Developed Disease-Specific Quality of Life Questionnaire (Wilqol) for Germany Moorthi C1 , Bade A1 , von Mackensen S2 , Overberg D1 , Auerswald G1 1 2 Prof. Hess Children´s Hospital, Bremen, Germany, Institute and Polyclinics of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany 35P30 Preliminary Study of VWF Clearance Analysing the VWF Propeptide Moret A, Cabrera N, Cid A, Haya S, Abad-Franch L, Aznar J Unidad de Hemostasia y Trombosis, Hospital Universitario La Fe, Valencia, Spain 35P31 Plasma ADAMTS13 Activities in Non-Human Primates and Rabbits Do Not Change Upon Administration of Recombinant VWF Varadi K, Rottensteiner H, Weber A, Gritsch H, Turecek PL, Muchitsch E-M Baxter Innovations GmbH, Vienna, Austria
Index of Poster Presenters cont’d 35P32 Experience with a VWF/FVIII Concentrate in Surgeries in Patients with von Willebrand Disease – Results from a German Prospective Post-Licensure Surveillance Scharrer I1 , Dörner T2 , Kadar J3 , Nowak-Göttl U4 , v Depka M5 , Feddern J6 1 2 University Clinic, Mainz, Germany, Charite, Berlin, Germany 3Practice for Transfusion Medicine, Cologne, Germany, 4 5 University Clinic, Münster, Germany, Werlhof Clinic, Hanover, Germany, 6Octapharma, Langenfeld, Germany 35P33 Latest Interim Results from a German Prospective Post- Marketing Surveillance of Treatment of von Willebrand Disease with a New Generation VWF/FVIII Concentrate Alesci S1 , Halimeh S2 , Kadar J3 , Nowak-Göttl U4 , Scharrer I5 , v. Depka M6 , Feddern J7 for the SET study group 1 2 University Clinic, Frankfurt, Germany, MVZ, Duisburg, Germany, 3Practice for Transfusion Medicine, Köln, Germany, 4 5 University Clinic, Münster, Germany, University Clinic, Mainz, Germany, 6Werlhof Clinic, Hannover, Germany, 7Octapharma, Langenfeld, Germany 35P34 1 + 1 = 3: A Family’s Experience of VWD Porter-Bishop L Haemophilia Foundation of New Zealand, Canterbury, New Zealand 35P35 Comparative Immunogenicity Assessment of Recombinant and Highly Purified Plasma-Derived Human von Willebrand Factor in Balb/C Mice Reipert B, Ahmad RU, Horling FM, Matthiessesn P, Turecek PL, Schwarz H-P and van Helden P Baxter BioScience, Vienna, Austria 35P36 Secondary Prophylaxis in Type III von Willebrand Disease: First Case in a Pediatric Patient Rodriguez I, Boggia B, Ferrari S, Raffo C, Mezzano R, Lemos F Centro Hospitalario Pereira Rossell, Montevideo, Uruguay 35P37 Evaluation of VWF Concentrate Activity Assays Employing Collagen Types I and III Stadler M, Janisch S, Zapfl C, Roemisch J Octapharma PPGmbH, Vienna, Austria 35P38 Comparison of Plasma-Derived and Recombinant von Willebrand Factor by Atomic Force Microscopy Seyfried BK 1 , Friedbacher G 1 , Schwarz HP 2 , Ehrlich HJ 2 , Turecek PL 2 , Rottensteiner H 2 1 Vienna University of Technology, and 2 Baxter Innovations GmbH, Vienna, Austria 35P39 In Vitro and In Vivo Cleavage of Human Recombinant VWF (rVWF) By ADAMTS13 Varadi K, Vejda S, Schreiner J, Gritsch H, Muchitsch E-M, Rottensteiner H Baxter Innovations GmbH, Vienna, Austria 35P40 Comparing the Pharmacokinetic Properties of Wilate® and Humate-P® in Subjects with Inherited von Willebrand Disease (VWD) - A Prospective, Randomised, Crossover Study Schwartz B1 , Powell J2 , Kessler C3 , Schindel F4 1 2 Octapharma U.S.A. Inc, Hoboken, NJ, U.S.A., University of California, Davis, Sacramento, U.S.A., 3Georgetown University Hospital, Washington, DC, U.S.A., 4Accovion Biostatistics, Marburg, Germany 35P41 Evaluation of Clinical Hemostatic Efficacy of Wilate Utilizing Subjective vs. Objective Criteria - A Way to Improve Accuracy and Comparability of Results in VWD Trials Kessler C1 , Schwartz B2 , Knaub S3 , Walter O3 , Schindel F4 , Hegener O3 1Georgetown University Hospital, Washington, DC, U.S.A., 2 3 Octapharma U.S.A. Inc, Hoboken, NJ, U.S.A., Octapharma AG, Lachen, Switzerland, 4Accovion Biostatistics, Marburg, Germany 35P42 Clinical Features and Types of von Willebrand Disease in Karachi, Pakistan Borhany M, Shamsi T, Naz A, Farzana T, Ansari S, Nadeem M Thrombosis and Haemostasis Unit of National Institute of Blood Disease & Bone Marrow Transplantation, Karachi, Pakistan 35P43 Effectiveness of DDAVP (Minirin Parenteral) in Subjects with von Willebrand Disease (VWD) Type 1 and 2a Siegmund B, Richter H, Pollmann H Institute for Thrombosis and Hemostasis, Muenster, Germany 91 Posters, Tuesday and Wednesday
Page 1 and 2:
Hemophilia Saturday, July 10 - Wedn
Page 3 and 4:
Pre-Congress Sessions cont’d 10:3
Page 5 and 6:
Pre-Congress Sessions cont’d 15:0
Page 7 and 8:
Congress Sessions cont’d S1.6 - M
Page 9 and 10:
Congress Sessions cont’d S2.5 - M
Page 11 and 12:
Congress Sessions cont’d n Long T
Page 13 and 14:
Congress Sessions cont’d M2.4 - M
Page 15 and 16:
Congress Sessions cont’d Tuesday,
Page 17 and 18:
Congress Sessions cont’d 14:15 -
Page 19 and 20:
Congress Sessions cont’d T3.4 - M
Page 21 and 22:
Congress Sessions cont’d n Inhibi
Page 23 and 24:
Congress Sessions cont’d W2.4 - L
Page 25 and 26: Index of Speakers cont’d Halimeh,
Page 27 and 28: Index of Poster Presenters Sunday a
Page 29 and 30: Index of Poster Presenters cont’d
Page 75: Index of Poster Presenters cont’d
show all

Final Program in it's entirety - MyGirlsBlood

Create successful ePaper yourself

Delete template?

Save as template?